Akero Therapeutics Stock Skyrockets as Phase 2b MASH Trial Yields Groundbreaking Results

Stock Price Surge:
Akero Therapeutics' stock price doubled following the release of preliminary topline results from the Phase 2b SYMMETRY study, which showed statistically significant reversal of compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH)234.

Clinical Trial Results:
The study demonstrated that 39% of patients treated with 50mg efruxifermin (EFX) experienced reversal of cirrhosis with no worsening of MASH, compared to 15% for placebo, among patients with baseline and week 96 biopsies2.

ITT Analysis:
In the Intent to Treat (ITT) population, 29% of patients in the 50mg EFX group experienced reversal of cirrhosis with no worsening of MASH, compared to approximately 12% in the placebo group2.

Analyst Reaction:
Analysts with Evercore ISI described the data as "transformational" in a note to investors, highlighting the potential of efruxifermin in treating MASH45.

Future Plans:
Akero Therapeutics plans to continue evaluating 50mg EFX in their ongoing Phase 3 SYNCHRONY study2.

Sources:

2. https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-reports-preliminary-topline-results-showing

3. https://www.biopharmadive.com/news/akero-efruxifermin-mash-reverse-cirrhosis-symmetry-results/738334/

4. https://www.cafepharma.com/content/akeros-stock-doubles-midphase-mash-trial-generates-transformational-data-analyst

5. https://biotechjobs.io/2025/01/27/akeros-stock-doubles-as-midphase-mash-trial-generates-transformational-data-analyst/